Table 1.
Sex, male/female, n | 59/14 |
Race, Caucasian, % | 99 |
Age, yr, at ESRD, median (min−max) | 26 (11−71) |
Time on dialysis, mo median (min−max) | 33 (1−190) |
Deafness (n) | 48 |
Age, yr, at hearing aid, median (min−max) | 24 (6−55) |
Age, years, at first TP, median (min−max) | 28 (12−73) |
Duration of post-TP follow-up, yr, median (min−max) | 16 (1−42) |
Living/deceased donor (n) | 13/80 |
Number of TPs, n | 93 |
Second/third TP | 16/2 |
Immunosuppressive regimen, % | |
Induction | 100 |
Cyclosporine | 69 |
Tacrolimus | 31 |
Mycophenolate mofetil | 25 |
Azathioprine | 73 |
Sirolimus | 1 |
Corticosteroids | 98 |
ESRD, end-stage renal disease; min−max, minimum−maximum; TP, transplantation.